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(IGFBP-1) may have an association with insulin resistance
and B-cell secretory dysfunction. Present study is under-
taken to explore the independent association of IGF-1 and
IGFBP-1with two basic defects in type 2 diabetic patients
in a Bangladeshi population.
Methods: Sixty eight type 2 diabetes mellitus (DM) subjects
are studied along with age-, sex- and BMI-matched 61
healthy controls without family history of diabetes or
prediabetes. Insulin, free IGF-1 and IGFBP-1 are measured
by the standard ELISA method. Insulin secretory capacity
(HOMA B) and insulin sensitivity (HOMA S) are calculated
using fasting glucose and fasting insulin by HOMA-
CIGMA software.
Results: Fasting free IGF-1 and IGFBP-1 levels are not
significantly different between the study groups. But the
level of free IGF-1 is significantly higher (p= 0.03) in type
2 DM subjects compared to controls in the low BMI group
(BMI 6 23). In stepwise multiple regression analysis,
positive association of HOMA B with free IGF-1 is evident.
Similarly positive association of HOMA B and HOMA S
with IGFBP-1 is shown in different models. In the same
analysis, both free IGF-1 and IGFBP-1 are inversely associ-
ated with fasting insulin in different models of stepwise mul-
tiple regression analysis.
Conclusion: Both IGF-1 and IGFBP-1 are negatively asso-
ciated with fasting insulin levels. Moreover B-cell secretory
dysfunction is positively associated with IGF-1 and both
B-cell secretory dysfunction and insulin sensitivity are also
positively associated with IGFBP-1 in type 2 diabetic
patients.
Keywords: BMI; Free IGF-1; IGFBP-1; IGT; Type 2 DM
 2014 Taibah University. Production and hosting by Elsevier
Ltd. All rights reserved.
Introduction
Insulin like growth factor-1 (IGF-1) is a peptide hormone that
shares nearly 50% amino acid sequence homology with proin-
sulin, and like insulin, is composed of an alpha and a beta
chain connected by disulfide bonds. It is a multipotent growth
factor with important effect on normal tissue growth and
metabolism. IGF-1 is similar in structure to insulin. Reduced
IGF-1 level has been proposed to have a role in diabetes.1–3
It lowers blood glucose while at the same time lowering serum
insulin level in normal volunteers. Its mechanism of action ap-
pears to be independent of activation of the insulin receptor
although the role of IGF-1 in normal carbohydrate metabo-
lism remains incompletely defined. IGF-1 also improves insu-
lin resistance both in type 2 diabetes and in subjects with
more severe insulin resistance.4 IGFs (insulin like growth fac-
tors), which in an unbound form induce glucose and amino
acid uptake, circulate bound to insulin like growth factor bind-
ing proteins (IGFBPs), which modulate their bioavailability
and activity.5 IGFBPs are a group of structurally closely re-
lated proteins. In addition to their hormonal binding function,
they modulate the activities of IGF-1 and IGF-2 and are in-
volved in a variety of metabolic functions affecting glucose
and insulin metabolism.6,7 Insulin is considered the primary
regulator of IGFBP-1 level.8 IGFBP-1 level has been shown
to be elevated in type 1 diabetes and in patients with insulin
resistance syndromes. Type 2 diabetes tends to have low serum
IGFBP-1 level. Patients with deficiency of insulin tend to have
elevated IGFBP-1 level.9
In an article of the Biochemical Journal, da Silva-Xavier
et al.10 reported a method to directly compare the effects of
knocking down expression of the insulin receptor and IGF-1
receptor genes in the MIN-6 b-cell line. Surprisingly, loss of
either receptor caused a total loss of glucose-mediated insulin
secretion but not that mediated by depolarizing agents. This
could be explained if hybrid IGF – insulin receptors were re-
quired for glucose-induced secretion which indicates that insu-
lin and IGF-1 receptors have distinct roles in maintaining the
capability of b-cells to secrete insulin. Indeed, the study identi-
fies such differences. Firstly, lack of IGF-1 results in a dysreg-
ulation of mechanisms controlling cellular ATP level, which
would clearly impact on the ability of glucose to bring about
insulin secretion. Loss of insulin receptors, on the other hand,
does not have such a drastic effect on the cellular ATP level,
but does have a dramatic effect on the ability of glucose to reg-
ulate expression of key glucoregulatory genes, an effect not
seen in IGF-1 receptor knock-downs. Freund et al.11 have
shown that even in myeloma cell line functional insulin and
IGF-1 receptors are present and through them insulin and
IGF-1 regulate mitogenesis and glucose metabolism.
Type 2 diabetes as well as prediabetic states, including im-
paired fasting glucose and impaired glucose tolerance, are
associated cross-sectionally with altered circulating level of
IGF-1 and its binding proteins (IGFBPs). Administration of
recombinant human IGF-1 has been reported to improve insu-
lin sensitivity in healthy individuals as well as in patients with
insulin resistance and type 2 diabetes. Further, IGF-1 may
have beneficial effects on systemic inflammation, a risk factor
for type 2 diabetes and on pancreatic b-cell mass and function.
There is a considerable inter-individual heterogeneity in
endogenous level of IGF-I and its binding proteins.12 In recent
studies of IGF-1 and diabetes were restricted to elderly popu-
lations13 or had limited sample size.14 Also there is some incon-
sistency in their findings as one of these studies14 found a
positive association with decreasing IGF-1 while the other
study did not find an association.13 A recent study of Ban-
gladeshi prediabetic subjects showed that IGF1 and IGFBP-
1 seem to be negatively associated with fasting glucose in im-
paired glucose tolerance (IGT) subjects and insulin sensitivity
(HOMA S) may also be negatively associated with IGFBP-1
in IGT subjects.15 However, the association was not investi-
gated in Bangladeshi type 2 diabetic subjects. So, the present
study has been undertaken to explore whether serum insulin
like growth factor-I (IGF-I) and insulin like growth factor
binding protein-1 (IGFBP-1) levels are associated with pri-
mary defects (insulin secretory capacity of beta-cells and insu-
lin resistance) of type 2 diabetes.
Materials and Methods
This cross-sectional observational study was conducted in
the Bangladesh Institute of Research and Rehabilitation in
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Diabetes, Endocrine and Metabolic Disorders (BIRDEM),
Dhaka. A group of 68 type 2 DM subjects were selected pur-
posively from the Out-Patient Department (OPD) of BIR-
DEM, along with a group of 61 age-, sex- and BMI-matched
healthy subjects without family history of diabetes as Controls
considering the same socio-economic status. Written consent
was obtained from all the volunteers; clinical examinations
were undertaken by a registered physician using a predesigned
questionnaire. In the study newly diagnosed Type 2 DM and
patients who suffered from type 2 DM for one year were in-
cluded and the patients with serious illness, pregnant women
and person with mental disorders were excluded.
Anthropometric measurements were taken using standard
methods. Subjects were requested to come on a scheduledmorn-
ing, after overnight fasting for the fasting blood sample; subjects
were then given 75 g anhydrous glucose dissolved in 250 ml
water. Blood was taken at fasting conditions and 2 h after glu-
cose loading. Serum glucose, cholesterol, triglyceride and high
density lipoprotein (HDL) were determined by the enzymatic
colorimetric method, using commercial kits (Randox Laborato-
ries Ltd., UK). The low density lipoprotein (LDL) cholesterol in
serum was calculated by using the formula: LDL choles-
terol = Total cholesterol  (TG/5 + HDL cholesterol). Serum
insulin level was determined by the enzyme linked immunosor-
bent assay (ELISA)method (LincoResearch Inc., USA). Serum
free IGF-1 and IGFBP-1 concentrations were measured by the
enzyme linked immunosorbent assay (ELISA) method (Ray
Biotech, USA). Insulin secretory capacity (HOMAB) and insu-
lin sensitivity (HOMA S) were calculated from fasting glucose
and fasting insulin using HOMA-CIGMA software.16
Statistical analysis
Statistical analysis was performed using SPSS (Statistical
Package for Social Science) software for Windows version 10
(SPSS Inc., Chicago, Illinois, USA). All data were expressed
as mean ± SD (standard deviation), median and/or percent-
age (%) as appropriate. The statistical significance of differ-
ences between the values was assessed by ANOVA or Mann-
Whitney U test (as appropriate). Logistic and multiple regres-
sion was fitted to the data. A two-tailed p value of <0.05 was
considered as statistically significant.
Results
Clinical characteristics of the study subjects
Waist to Hip Ratio (WHR) was significantly (p= 0.007) high-
er in Type 2 DM subjects compared to than in Controls. Other
anthropometric measurements (BMI, MUAC and Triceps)
showed no difference between controls and type 2 DM subjects
(Table 1).
Insulinemic status of the study subjects
Fasting serum insulin level was significantly higher in type 2
DM (p= 0.01) compared to that in Controls. Insulin sensitiv-
ity (HOMA S) and B cell function (HOMA B) was signifi-
cantly lower in type 2 DM (p= 0.001) compared to that in
Controls. Fasting serum free IGF-1 level and IGFBP-1 level
of type 2 DM subjects showed no significant difference com-
pared to that in Controls (Table 1). But the level of free
IGF-1 was significantly higher (p= 0.03) in type 2 DM sub-
jects compared to their counterpart controls in the low BMI
group (BMI 6 23). It was also found that controls with
BMI > 23 had significantly higher level of free IGF-1 com-
pared to lean controls with BMI 6 23 (p= 0.05). But the level
of IGFBP-1 was not significantly different in the low BMI
group and high BMI group (BMI > 23) (Table 2).
Table 1: Clinical and biochemical characteristics of the study subjects.
Variable Control (n= 61) Type 2 DM (n= 68)
Age (Years) 36 ± 6 44 ± 9
BMI (kg/m2) 25.4 ± 3.8 25.3 ± 3.2
Waist to hip Ratio (WHR) 0.91 ± 0.05 0.93 ± 0.04*
MUAC (mm) 298 ± 27 289 ± 45
Triceps (mm) 14.6 ± 5.0 13.5 ± 4.7
Systolic blood pressure (mmHg) 115 ± 9 119 ± 21
Diastolic blood pressure (mmHg) 77 ± 9 80 ± 10
Fasting glucose (mmol/l) 5.2 ± 0.5 7.2 ± 1.6*
Postprandial glucose (mmol/l) 5.9 ± 1.7 14.1 ± 3.1*
Fasting Insulin (pmol/l) 51.7 (7.8–155.9) 69.3 (17.4–525.3)*
HOMA B 99 (21–187) 62 (14–296)*
HOMA S 86 (29–554) 59 (9–256)*
Triglyceride (mg/dl) 136 (52–408) 181 (54–1050)*
Cholesterol (mg/dl) 192 (90–261) 209 (129–294)*
HDL-Cholesterol (mg/dl) 30 (13–59) 30 (15–47)
LDL-Cholesterol (mg/dl) 125 (46–203) 140 (55–204)
Free IGF-1 (pg/ml) 118.2 (39.4–486.1) 140.1 (19.9–803.5)
IGFBP-1 (ng/ml) 11.5 (1.1–83.97) 11.9 (0.68–146)
Results are expressed as M± SD.
*p< 0.05, significantly different compared to controls when using Student’s ‘t’ test. HOMA B= B cell function
assessed by homeostasis model assessment; HOMA S = insulin sensitivity assessed by homeostasis model assessment;
Free IGF-1 = free insulin like growth factor-1 and IGFBP-1 = insulin like growth factor binding protein-1.
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Correlation
Pearson correlation analysis has shown a significant associa-
tion of fasting serum triglyceride (r= 0.361, p= 0.03) and
cholesterol (r= 0.337, p= 0.04) with free IGF-1 in type 2
DM subjects. In the same analysis IGFBP-1 also showed a sig-
nificant association with fasting insulin (r= 0.426,
p= 0.001) and fasting HOMA S (r= 0.423, p= 0.001) in
type 2 DM subjects (Table 3).
In stepwise multiple regression analysis, when free IGF-1
was considered as a dependent variable with other independent
variables, it showed that free IGF-1 was negatively associated
with fasting insulin [model 6 (b= 1.029, p= 0.05), model 7
(b= 1.103, p= 0.048) and model 8 (b= 1.156,
p= 0.036)], fasting TG [model 6 (b= 0.093, p= 0.05),
model 8 (b= 0.142, p= 0.048) & model 9 (b= 0.494,
p= 0.01)] and positively associated with HOMA B [model 7
(b= 1.322, p= 0.05), model 8 (b= 1.343, p= 0.05)] and
WHR [model 9 (b= 0.354, p= 0.045)] in type 2 DM subjects
(Table 4).
In the same analysis, when IGFBP-1 was considered as a
dependent variable with other independent variables, it
showed that IGFBP-1 was positively associated with HOMA
S [model 1 (b= 0.366, p= 0.031), model 2 (b= 0.469,
p= 0.021), model 4 (b= 0.499, p= 0.02)], HOMA B [model
4 (b= 1.278, p= 0.017), model 5 (b= 1.168, p= 0.027),
model 6 (b= 1.054, p= 0.059), model 7 (b= 1.074,
p= 0.059), model 9 (b= 1.499, p= 0.015)] and inversely
associated with fasting insulin [model 4 (b= 0.940,
p= 0.031), model 5 (b= 0.856, p= 0.047) & model 9
(b= 1.214, p= 0.018)] in type 2 DM subjects (Table 5).
Fasting serum IGFBP-1 was negatively associated with
BMI (r= 0.33, p= 0.011) and positively associated with
HOMA S (r= 0.42, p= 0.001) in type 2 DM subjects using
the multiple regression curve analysis (Figs. 1 and 2).
Discussion
Impaired B cell function and/or insulin resistance is the pri-
mary pathogenic mechanism of type 2 diabetes. In the present
study, the studied diabetic subjects have also shown signifi-
cantly lower insulin sensitivity (HOMA S) and insulin secre-
tory capacity (HOMA B) compared to healthy control
subjects. In recent years it has been documented that free
IGF-1 and IGFBP-1 are associated with type 1diabetes as well
as with obesity.21 Studies on obese type 2 diabetic subjects
have shown an increasing tendency of free IGF-1 and a
decreasing tendency of IGFBP-1.17 Studies on obese IGT sub-
jects have also claimed similar results.19 In the present study,
Bangladeshi type 2 diabetic subjects seem to have increasing
tendency of free IGF-1 and IGFBP-1 but it was not statisti-
cally significant when compared to control subjects. Frystyck
et al. (1999) have shown that the level of free IGF-1 increased
in obese controls (BMI, 31.6 ± 0.7) compared to lean controls
(BMI, 22.8 ± 0.2), but in obese type 2 diabetes (BMI, 32.3
± 0.8) the level of free IGF-1 did not differ significantly from
either lean or obese controls.21 A study done on type 1 DM
subjects (Janssen et al., 1997) have shown that free IGF-1 level
was significantly lower compared to age- and sex-matched
healthy Controls. The author also found that age-adjusted free
IGF-1 level in subjects with diabetic retinopathy was higher than
those in subjects without diabetic retinopathy.23 Contradictory
Table 2: Serum free IGF-1 and IGFBP-1 levels on the basis of BMI category.
BMI category Variable Control Type 2 DM u/p value
Control vs DM
BMI 6 23 Free IGF-1 (pg/ml) 95.70 (39.4–161.53) 182.62 (72.32–365.45) 55.50/0.03
IGFBP-1 (ng/ml) 15.54 (6.33–49.76) 18.46 (3.34–146.0) 71.00/0.635
BMI > 23 Free IGF-1 (pg/ml) 149.52 (39.40–486.11) 130.93 (19.91–803.52) 214.0/0.960
IGFBP-1 (ng/ml) 9.96 (1.17–83.97) 11.22 (2.58–90.40) 623.50/0.434
Data are expressed as median (range) as appropriate. p value was calculated by Mann Whitney test. Free IGF-1 = free insulin like growth
factor-1; IGFBP-1 = insulin like growth factor binding protein-1.
Table 3: Correlation of serum free IGF-1 and IGFBP-1 with different variables among the study groups.
Group Fasting Glucose Fasting Insulin Triglyceride Cholesterol HOMA B HOMA S
Control Free IGF-1 r 0.116 0.099 0.295 0.086 0.056 0.106
p 0.582 0.639 0.152 0.683 0.789 0.614
IGFBP-1 r 0.16 0.186 0.227 0.043 0.062 0.29
p 0.275 0.205 0.120 0.773 0.676 0.153
Type 2 DM Free IGF-1 r 0.123 0.022 0.361 0.337 0.038 0.047
p 0.473 0.897 0.030 0.040 0.825 0.784
IGFBP-1 r 0.097 0.426 0.112 0.014 0.236 0.423
p 0.483 0.001 0.414 0.918 0.083 0.001
Data are expressed as correlation coefficient (Pearson’s correlation) r values and p= level of significance.
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results also exist in different studies where reduced IGF -1 level
has been proposed to have a role in diabetes.1–3
Another study suggested that type 2 DM leads to a decrease
in the IGF-I while elevating the IGFBP-1 level.17 In a repre-
sentative sample of US adults without clinical cardiovascular
disease, they found that low level of serum IGF-1 was posi-
tively associated with diabetes. When they examined the
association between serum IGF-1 and diabetes by age, low ser-
um IGF-1 was positively associated with diabetes only in sub-
jects <65 years of age and not in those >65 years of age.18
Sandhu et al. reported a positive association between low
IGF-1 level and glucose intolerance/diabetes in a sample of
615 subjects aged 45–65 years.14 In contrast, recently Rajpatak
Table 4: Multiple regression analysis of different factors affecting free IGF-1 in DM subjects.
Variables Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7 Model 8 Model 9
b p b p b p b p b p b p b p b p b p
F_GLU 0.159 0.362 0.213 0.217 0.213 0.224 0.208 0.247 0.242 0.176 0.287 0.387 0.357 0.313 0.293 0.398 0.137 0.669
TG 0.304 0.082 0.307 0.131 0.297 0.159 0.326 0.118 0.393 0.056 0.373 0.076 0.412 0.048 0.494 0.013
T_CHOL 0.006 0.975 0.009 0.965 0.065 0.756 0.250 0.270 0.295 0.220 0.299 0.205 0.170 0.435
F_INS_PM 0.044 0.811 0.141 0.524 1.029 0.056 1.103 0.048 1.156 0.036 0.825 0.106
HOMA S% 0.322 0.157 0.267 0.224 0.199 0.415 0.217 0.365 0.271 0.218
HOMA B% 1.215 0.070 1.322 0.059 1.343 0.051 0.774 0.236
BMI 0.133 0.519 0.020 0.925 0.251 0.249
WHR 0.273 0.144 0.354 0.045
NECK 0.516 0.017
R2 0.004 0.059 0.029 0.002 0.034 0.112 0.094 0.135 0.285
b stands for standardized regression coefficients. R2 for adjusted R square (Multiple coefficient of determination).
Table 5: Multiple regression analysis of different factors affecting IGFBP-1 in DM subjects.
Variables Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7 Model 8 Model 9
b p b p b p b p b p b p b p b p b p
HOMA S% 0.366 0.031 0.469 0.021 0.387 0.065 0.499 0.020 0.359 0.115 0.349 0.130 0.353 0.132 0.368 0.126 0.262 0.266
HOMA B% 0.191 0.328 0.468 0.123 1.278 0.017 1.168 0.027 1.054 0.059 1.074 0.059 1.084 0.061 1.499 0.015
F_INS_PM 0.383 0.229 0.940 0.031 0.856 0.047 0.786 0.077 0.792 0.080 0.786 0.087 1.214 0.018
F_GLU 0.538 0.062 0.450 0.991 0.433 0.137 0.455 0.132 0.468 0.130 0.551 0.068
BMI 0.260 0.159 0.180 0.411 0.161 0.482 0.182 0.441 0.148 0.514
NECK 0.137 0.507 0.123 0.564 0.080 0.731 0.224 0.347
WHR 0.069 0.702 0.092 0.626 0.026 0.892
IGF-1 0.086 0.638 0.123 0.555
TG 0.387 0.074
R2 0.107 0.107 0.121 0.193 0.221 0.206 0.181 0.157 0.230
b stands for standardized regression coefficients. R2 for adjusted R square (Multiple coefficient of determination).
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Figure 1: Relationship of serum IGFBP-1 with BMI in type 2
diabetic subjects.
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Figure 2: Relationship of serum IGFBP-1 with HOMA S in type 2
diabetic subjects.
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et al. did not find an independent association between IGF-1
and diabetes among 922 subjects aged >65 years from the
Cardiovascular Health Study.13
In recent years it has been decided that the cut-off point of
BMI for over weight in Asian populations should be 23 be-
cause in this BMI group body fat content in Asian population
is similar with European population with BMI < 25.24 On this
basis we have classified our subjects and it has been found that
in the low BMI group (BMI 6 23) the level of free IGF-1 was
significantly (p= 0.03) higher in type 2 DM subjects com-
pared to their counterpart controls. This result is supported
by another study done on European population where it has
been shown that free IGF-1 significantly increased in moderate
and severe obesity subjects compared to those with normal
BMI.19 A study of Korean population has reported similar re-
sults, namely, that free IGF-1 concentrations were significantly
elevated in obese subjects (free IGF-1, 1.46 ± 1.1 lg/l; BMI,
30 ± 2.5) when compared to controls (free IGF-1, 0.91
± 0.9 lg/l; BMI, 21.3 ± 1.4)..20
In this study, no significant difference of IGFBP-1 level was
observed between the low (BMI 6 23) and high (BMI > 23)
BMI group neither in type 2 DM subjects nor in controls.
But the studies have shown that obese people have significantly
lower values of IGFBP-1 compared to lean controls and obese
type 2 DM subjects.20,21 Another study done in USA have
shown that IGFBP-1 in type 1 diabetes was significantly higher
compared to healthy controls and type 2 DM subjects.22 In
stepwise multiple regression analysis free IGF-1 was inversely
associated with fasting insulin (model 6, model 7 and model
8) and positively associated with insulin secretory capacity
(model 7, model 8) in type 2 DM subjects. By using Pearson’s
correlation analysis, a significant association of fasting serum
triglyceride (r= 0.361, p= 0.03) with free IGF-1 was ob-
served in type 2 DM subjects which was also found in stepwise
multiple regression analysis where fasting triglyceride was in-
versely associated with free IGF-1 (model 6, model 8 and mod-
el 9) in type 2 DM subjects. So, dyslipidemia may affect on the
level of free IGF-1 in the blood or vice versa.
IGFBP-1 was significantly associated with fasting insulin
and fasting HOMA S in the simple Pearson’s correlation which
is also reflected in stepwise multiple regression analysis where
IGFBP-1 showed itself to be inversely associated with fasting
insulin (model 4, model 5, model 9) and positively associated
with HOMA S (model 1, model 2, model 4) and HOMA B
(model 4, model 5, model 6, model 7, model 9) in type 2
DM subjects. The positive association of IGFBP-1 and
HOMA S was also observed in the multiple regression curve
analysis (r= 0.42, p= 0.001) in type 2 DM subjects.
Conclusion
Both IGF-1 and IGFBP-1 are negatively associated with fast-
ing insulin. IGF-1 is positively associated with insulin secre-
tory capacity and IGFBP-1 is positively associated with both
insulin secretory capacity and insulin sensitivity in Bangladeshi
type 2 diabetic subjects.
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